Cat. #161764
TOV-21G cell line
Cat. #: 161764
Availability: 8-10 weeks
Organism: Human
Tissue: Derived from solid tumors of ovarian cancer patient
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Anne-Marie Mes-Masson and Diane Provencher
Institute: Centre Hospitalier de L’université de Montréal
Primary Citation: Provencher et al. 2000. In Vitro Cell.Dev.Biol.-Animal 36(6):357-61. PMID:10949993
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: TOV-21G cell line
- Alternate name: TOV-21G
- Cancer type: Ovarian cancer
- Cancers detailed: Clear cell carcinoma
- Research fields: Cancer
- Organism: Human
- Gender: Female
- Tissue: Derived from solid tumors of ovarian cancer patient
- Donor: Grade 3 - Stage IIIC; Mutations: TGF-b-II Exon 2, K-RAS2; Pre-treatment
- Crispr: No
- Receptors of note: No
- Description: Spontaneous immortalised epithelial ovarian cancer cell line derived from a patient never exposed to chemotherapy or radiation therapy. Cell line retains cahracteristics of the original epithelial ovarian cancers from which it was derived.
- Cellosaurus id: CVCL_3613
Handling
- Growth medium: OSE medium consisting of 50:50 medium 199:105 (Sigma), with 2.5 μg/mL amphotericin B and 50 μg/mL gentamicin
References
- Yang et al. 2025. Nat Commun.16(1):2071. PMID: 40021646
- Brodeur et al. 2021. Sci Rep. 14.11(1):18183. PMID: 34521878
- Beltran et al. 2014. Clin Cancer Res. 20(11):2947-58. PMID: 24727326
- Loganathan et al. 2012. PLoS One. 7(8):e43577. PMID: 22952709
- Kandala & Srivastava. 2012. BMC Med. 10:9. PMID: 22280969
- Provencher et al. 2000. In Vitro Cell Dev Biol Anim. (36): 357–361. PMID:10949993
![Anti-CAR Whitlow Linker [1C3C3]](https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-300x322.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-280x300.jpg 280w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-954x1024.jpg 954w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-768x824.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 1193w)
